Product Description: Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].
Applications: COVID-19-anti-virus
Formula: C28H35NO3
References: [1]Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64./[2]Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092.
CAS Number: 1818428-24-8
Molecular Weight: 433.58
Compound Purity: 99.16
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Cannabinoid Receptor;HIF/HIF Prolyl-Hydroxylase;PPAR
Deutsch
English
